drugset / Trial / NCT00397631

Initial Combination With Pioglitazone Study (0431-064)

NCT00397631

Phase 3 Completed 520 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

A clinical study to evaluate the safety and efficacy of the initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes mellitus not on treatment with insulin or oral antihyperglycemic therapy.

Timeline

Start
2006-12-19
Primary completion
2008-06-28
Completion
2008-06-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pioglitazone Small molecule 30 mg Oral
Subject Sitagliptin Small molecule 100 mg Oral